drugset
drugset / Trial / NCT00004494

Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis

NCT00004494 ↗

Phase 1 Completed 18 enrolled Stony Brook University FDA Office of Orphan Products Development · collabState University of New York · collab
Treatment

Summary

OBJECTIVES: I. Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with acute respiratory distress syndrome. II. Evaluate the safety and pharmacodynamic activity of this peptide in these patients.

Timeline

Start
1998-09
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Vasoactive Intestinal Peptide Peptide — Intravenous

Indications

adult acute respiratory distress syndrome infectious disease with sepsis